Area studies

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

Retrieved on: 
Wednesday, March 6, 2024
Type 2 diabetes, Week, PD, Treatment, Cancer, Food, GLP1, Conference, ATTD, Biomarker, Hypoglycemia, DSM-IV codes, Area studies, Poster, C-peptide, Osteopathic medicine in Canada, Pharmaceutical industry

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, today announced three poster presentations presenting long-term 26 week follow-up data from patients treated with BMF-219, enrolled in the escalation portion of the ongoing Phase II clinical study (COVALENT-111), at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place in Florence, Italy from March 6-9, 2024. This clinical data from all dosing cohorts initiated to date as of February 12, 2024 from the Escalation Phase of COVALENT-111 will be featured during a Poster Discussion Presentation and two Poster Viewing Presentations at ATTD. Biomea will showcase the following three e-poster presentations:

Key Points: 
  • Please find a link here to our website where the poster presentations and discussion will be available.
  • A higher proportion of patients treated with 200mg QD achieved a clinically significant reduction in HbA1c compared to 100mg QD dosing.
  • A durable glycemic response (≥1.0% HbA1C reduction) was seen in 20% and 36% of patients in once daily 100 mg and 200 mg cohorts, respectively.
  • A PK study further assessing the optimal use of BMF-219 to ensure minimal variability of exposure is currently under way.

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Retrieved on: 
Wednesday, March 6, 2024
Neuropharmacology, Pharmacology, Algorithm, Microelectrode array, SOT, Artificial intelligence, Data management, Product management, Society of Toxicology, Salt Palace, Electrophysiology, Society, Organoid, Harvard Bioscience, Safety, Area studies, DSI, ChromeOS, HBIO, MEA, Machine learning, Research, Mesh, Environment, Online shopping

Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.

Key Points: 
  • Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
  • The Company’s industry-leading GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system.
  • The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
  • The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology.

AITX’s RAD Deploys Record Number of Devices in February

Retrieved on: 
Tuesday, March 5, 2024
AI, PSP, The Security Institute, RAD, CPP, ROSA, Theft, Area studies, Artificial intelligence, AVA, Mobile phone

Detroit, Michigan, March 05, 2024 (GLOBE NEWSWIRE) -- Robotic Assistance Devices (RAD), a wholly owned subsidiary of Artificial Intelligence Technology Solutions, Inc., (the “Company”) (OTCPK:AITX), is proud to announce that February, 2024 was the biggest month in RAD’s history, in terms of devices that began invoicing. This milestone underscores RAD's continuing ability to grow revenues at an accelerating pace by increasing the number of devices billing month over month.

Key Points: 
  • This milestone underscores RAD's continuing ability to grow revenues at an accelerating pace by increasing the number of devices billing month over month.
  • Steve Reinharz, CEO of AITX and RAD, expressed his enthusiasm for this achievement, stating, “This is one of many milestones important on our journey towards achieving operational profitability.
  • We continue to be focused on increasing the number of devices that can be built, deployed, and begin billing any given month.
  • AITX, through its subsidiary, Robotic Assistance Devices , Inc. (RAD), is redefining the $25 billion (US) security and guarding services industry through its broad lineup of innovative, AI-driven Solutions-as-a-Service business model.

NUAIR® Preps Northeast for Cross-Border UAS Operations

Retrieved on: 
Tuesday, March 5, 2024
Nav Canada, UAS, Human, Safety, Aircraft, Federal Aviation Administration, Area studies, Travel, Airline

SYRACUSE, N.Y., March 05, 2024 (GLOBE NEWSWIRE) -- Following a string of critical approvals and operational readiness missions, NUAIR® is prepping the Northeastern United States for cross-border uncrewed aircraft system (UAS) operations.

Key Points: 
  • SYRACUSE, N.Y., March 05, 2024 (GLOBE NEWSWIRE) -- Following a string of critical approvals and operational readiness missions, NUAIR® is prepping the Northeastern United States for cross-border uncrewed aircraft system (UAS) operations.
  • These operations will prove out safe integration of UAS into the national airspace with the opportunity for cross-border international collaboration and regulatory harmonization.
  • In 2023, NUAIR received a Special Flight Operations Certificate (SFOC) from Canada authorizing our team to perform UAS operations with U.S. pilots and U.S. aircraft in Ontario, Canada.
  • NUAIR looks forward to being the activator for these cross-border UAS operations in the new year.

ONWARD® Medical Awarded 10th Breakthrough Device Designation for Brain-Computer Interface (BCI) from US FDA

Retrieved on: 
Thursday, February 29, 2024
Nature, SCI, Artificial intelligence, Paralysis, BCI, FDA, ARC, Food, Euronext, BDD, Learning, Communication, History, Walking, Spinal cord, Movement, Area studies, Brain, Medical device

This is the tenth FDA BDD awarded to ONWARD Medical.

Key Points: 
  • This is the tenth FDA BDD awarded to ONWARD Medical.
  • The designation is reserved for novel, cutting-edge therapies addressing an unmet need and provides many potential regulatory and reimbursement advantages.
  • This latest award gives ONWARD Medical priority FDA review, the opportunity to interact with FDA experts throughout the pre-market regulatory review phase, and the potential to seek additional reimbursement for its ARC-BCI System.
  • “Brain-computer interface technology unlocks the transformative potential to enhance ARC-IM with thought-driven control of movement after paralysis,” said ONWARD Medical CEO Dave Marver.

AITX’s RAD Begins Production Run of 1000 Next Generation RIO Solar-Powered Security Towers

Retrieved on: 
Tuesday, February 27, 2024
Generation IV reactor, RAD, Origami Angel, Area studies, Artificial intelligence, Theft

Detroit, Michigan, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Robotic Assistance Devices (RAD), a subsidiary of Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCPK:AITX), today announced that it has begun production of 1000 units of the next generation (Gen 4) of its RIO™ solar-powered, mobile security solution.

Key Points: 
  • Steve Reinharz, CEO/CTO of AITX and RAD commented, “Generation 4 of both RIO and ROSA has been a huge undertaking for the entire Company.
  • Every component and stage of the manufacturing process has been scrutinized to find ways to reduce costs while improving performance.
  • Reinharz continued, “The potential revenue from the successful deployment of 1000 RIO units, when added to our existing revenues is significant.
  • RAD expects to continue to attract new business as it converts its existing sales opportunities into deployed clients generating a recurring revenue stream.

American Institutes for Research Announces New CEO and Board Chair

Retrieved on: 
Wednesday, February 21, 2024
African Americans, University, Education, Sale, Climate change, Student, Cambridge University Press, Faculty, Ethnic group, Social science, Social, Book, American Psychological Association, Harvard University Press, Policy, Guggenheim Fellowship, American Educational Research Association, Behavioural sciences, Psychology, National academy, Area studies, Public opinion, American Academy, Politics, Russell Sage Foundation, Harvard University, Stanford University, National Science Foundation, Rutgers University, School, AIR, UCLA, Public, Management

Lawrence D. Bobo , the dean of social science at Harvard University, is the new chair of the AIR Board of Directors.

Key Points: 
  • Lawrence D. Bobo , the dean of social science at Harvard University, is the new chair of the AIR Board of Directors.
  • Heppen is the seventh president and CEO in AIR’s 77-year history, and the first woman to serve in the role.
  • She stepped down from the AIR Board of Directors after serving as its chair for more than 25 years.
  • Bobo has been a member of the AIR Board since 1997 and most recently served as vice chair.

Parsons Wins $25 Million Transit Improvement Contract from City of Oakland

Retrieved on: 
Tuesday, February 20, 2024
Oak Street, Quality of life, City, Transport, Airport, Travel, Safety, Element, PSN, Area studies, Parsons Corporation, Pedestrian, Road

This $25 million contract includes designs for eight at-grade intersections, a multiuse trail, traffic signal plans, and represents new work for Parsons.

Key Points: 
  • This $25 million contract includes designs for eight at-grade intersections, a multiuse trail, traffic signal plans, and represents new work for Parsons.
  • Parsons will also deliver feasibility studies to analyze grade separated railroad crossing features, geometric configurations and equipment upgrades.
  • Parsons has decades of experience designing, delivering, and protecting the infrastructure that connects our communities around the world, including roads and highways; bridges; passenger and freight rail; public transit; airports; and ports and waterways.
  • To learn more about Parsons’ rail and transit expertise, visit https://www.parsons.com/rail-transit/.

Canada Announces Over $15 million to Support Canadian Mining Sector at the 2024 Prospectors and Developers Association of Canada Convention

Retrieved on: 
Wednesday, March 6, 2024
Prospectors, INRP, Magneto, Mining, Investment, Mineral, Transport, Government, Natural Resources, Metal, PDAC, CFP, Organization, Area studies, Recycling, Partnership

And as the world moves toward net zero by 2050, demand for Canada's mineral resources, especially critical minerals, will only increase.

Key Points: 
  • And as the world moves toward net zero by 2050, demand for Canada's mineral resources, especially critical minerals, will only increase.
  • That is why, yesterday at the 2024 Prospectors and Developers Association of Canada (PDAC) convention, the Honourable Jonathan Wilkinson, Minister of Energy and Natural Resources, announced federal investments of over $15 million in projects to increase Indigenous participation and support the development of Canada's critical minerals sector.
  • Minister Wilkinson also announced the launch of the first call for proposals for Indigenous grants under the Critical Minerals Infrastructure Fund (CMIF).
  • At least $25 million of this funding is dedicated to Indigenous communities' capacity building to support their participation in critical minerals development.

Alamar Biosciences Announces the Commercial Launch of Ultra-high Sensitivity NULISAseq™ CNS Disease Panel 120 and NULISAqpcr™ pTau-217 Assays

Retrieved on: 
Tuesday, March 5, 2024
Parkinson's disease, Incidence, Body fluid, Mevalonate pathway, Doctor of Philosophy, Chemistry, MD, Professor, Area studies, Ageing, GMT, Biomarker, CNS, Fluid mechanics, Dementia, Proteomics, CSF, Diagnosis, Plasma, Physiology, Research, Partnership

FREMONT, Calif., March 5, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, announced today the commercial launch of the NULISAseq CNS Disease Panel 120 for highly multiplexed protein analysis of all the critical pathways implicated in major neurological disorders, and the NULISAqpcr pTau-217 Assay (ALZpath antibody) for focused studies of this important biomarker in dementia research. Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies. The launch of these two products represents another important milestone in the company's goal to deliver high-sensitivity protein analysis from biofluids to enable earlier diagnosis of disease and better prediction of therapeutic outcomes. The products are expected to ship in Q2 2024. 

Key Points: 
  • Data demonstrating the superior performance over existing assays highlighted at the Alzheimer's Disease and Parkinson's Disease (AD/PD™ 2024) international conference in Lisbon, Portugal.
  • Both assays benefit from the unparalleled sensitivity of the NULISA™ chemistry and are run on the fully automated ARGO™ HT System that streamlines the time to complete large cohort studies.
  • The Alamar products represent a significant advancement in Alzheimer's Disease research, says Dr. Henrik Zetterberg.
  • This research depends on the availability of biomarkers to detect disease earlier and distinguish between highly related dementia disorders.